Table 1

Patient characteristics

ADA positive
N=21
ADA negative
N=36
P value
Age at diagnosis, years (SD)22.0 (7.9)30.0 (11.8) <0.001***
Age at time of treatment, years (SD)31.9 (9.1)42.9 (11.1) 0.03*
Disease duration, months (SD)119 (76)151 (108)NS
Gender (Female:Male) (%)16:5 (76:24)34:2 (94:6) 0.04*
Ethnicity, n (%)
Afro-Caribbean5 (24)6 (17)NS
Caucasian9 (43)19 (53)NS
South Asian3 (14)6 (17)NS
East Asian3 (14)2 (5)NS
Other1 (5)3 (8)NS
Indication for treatment, n (%)
Nephritis10 (48)7 (19)NS
Arthritis5 (24)11 (31)NS
Haematological3 (14)2 (6)NS
Neuro-psychiatric0 (0)1 (3)NS
Serositis1 (5)3 (8)NS
Cutaneous6 (29)9 (25)NS
Other3 (14)3 (8)NS
Additional treatment, n (%)
Hydroxychloroquine10 (48)20 (56)NS
Azathioprine5 (24)5 (14)NS
Mycophenolate mofetil4 (19)4 (11)NS
Methotrexate0 (0)4 (11)NS
Prednisolone17 (81)27 (75)NS
Cyclophosphamide†15 (71)22 (61)NS
Disease activity at the time of treatment
Complement C3 (g/L) (SD)0.76 (0.29)0.69 (0.24)NS
Anti-dsDNA titres (IU) (SD)411.7 (651.6)699.8 (874.2)NS
Global BILAG score (SD)15.8 (10.2)13.5 (5.6)NS
Disease activity 6 months post-treatment
Complement C3 (g/L) (SD)0.91 (0.27)0.83 (0.24)NS
Anti-dsDNA titres (IU) (SD)201.4 (369.6)682.0 (1009.0) 0.04*
Global BILAG score (SD)6.4 (5.4)7.4 (5.4)NS
  • *p<0.05; ***p<0.001.

  • †Given in combination with rituximab therapy.

  • ADA, antidrug antibody;BILAG, British Isles Lupus Assessment Group; dsDNA, double-stranded DNA; NS, not significant.